title: Population pharmacokinetics of tazobactam/piperacillin in Japanese patients with community-acquired pneumonia.
abstract: The population pharmacokinetics on tazobactam/piperacillin (TAZ/PIPC; 1:8, 4.5 g x 3) was analyzed in Japanese patients with community-acquired pneumonia using the Nonlinear Mixed Effect Model version VI. Analysis by the one-compartment model yielded the following results for PIPC: total clearance (CL) = 8.22+(Ccr-71.4) x 0.0561 (L/hr), distribution volume (Vd) = 13.7 (L). The pharmacokinetic parameters for TAZ were: CL = 8.67 + (Ccr-71.4) x 0.0682 (L/hr), Vd = 14.4 (L). Of the pharmacokinetic parameters of PIPC, CL included Ccr as a variation factor, whereas the Vd included no variation factor. Because PIPC is excreted into the urine in the unchanged form, its pharmacokinetic factors seem to reflect the renal function status. In this study of patients with community-acquired pneumonia, the mean Vd per body weight was 0.26 L/kg, and the results suggested an increase of the Vd in patients with community-acquired pneumonia as compared with the value in healthy adults.
authors.affiliation: Department of Pharmacy, Kitasato University East Hospital.
authors.forename: Yukihiro
authors.initials: Y
authors.lastname: Hamada
authors.affiliation: Pharmacy Practice and Science II, Kitasato University East Hospital, School of Pharmacy, Kitasato University.
authors.forename: Saki
authors.initials: S
authors.lastname: Takahashi
authors.affiliation: Department of Pharmacy, Kitasato University East Hospital.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Hirayama
authors.affiliation: Infectious Disease Science, Kitasato University, Kitasato Institute for Life Sciences.
authors.forename: Keisuke
authors.initials: K
authors.lastname: Sunakawa
authors.affiliation: Department of Pharmacy, Kitasato University East Hospital.
authors.forename: Masakazu
authors.initials: M
authors.lastname: Kuroyama
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000465:Algorithms; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics*; D017714:Community-Acquired Infections / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010397:Penicillanic Acid / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D010878:Piperacillin / Q000493:pharmacokinetics; D000077725:Piperacillin, Tazobactam Drug Combination; D011014:Pneumonia / Q000188:drug therapy*
chemical_list: D000900:Anti-Bacterial Agents; D000077725:Piperacillin, Tazobactam Drug Combination; D010397:Penicillanic Acid; D010878:Piperacillin